https://edmedrxp.com/ Clinical Knowledge. Precision Prescribing. en Mon, 27 Jul 2026 20:23:40 GMT https://edmedrxp.com/deprescribing-polypharmacy-structured-clinical-approach-geriatric/ https://edmedrxp.com/deprescribing-polypharmacy-structured-clinical-approach-geriatric/ As polypharmacy continues to rise among aging and medically complex US patients, deprescribing has emerged as a critical—and underutilized—clinical skill. This roadmap walks prescribers through evidence-based protocols for identifying inappropriate medications, managing discontinuation safely, and communicating treatment changes in ways that preserve patient trust and reduce medicolegal exposure. EdMedRxP Prescribing Practice & Policy Mon, 27 Jul 2026 20:22:05 GMT https://edmedrxp.com/pharmacogenomics-genetic-testing-prescribing-gap-cyp450-tpmt/ https://edmedrxp.com/pharmacogenomics-genetic-testing-prescribing-gap-cyp450-tpmt/ Pharmacogenomic testing offers clinicians an unprecedented window into individual drug metabolism, yet widespread adoption in routine practice remains elusive. This article examines the structural, financial, and educational barriers that prevent CYP450 and TPMT testing from becoming standard of care—and offers practical frameworks for integrating genetic data into clinical workflows today. EdMedRxP Clinical Pharmacology Mon, 27 Jul 2026 20:22:05 GMT https://edmedrxp.com/cytochrome-p450-drug-interactions-polypharmacy-clinical-guide/ https://edmedrxp.com/cytochrome-p450-drug-interactions-polypharmacy-clinical-guide/ Cytochrome P450 enzyme interactions remain one of the most underrecognized drivers of adverse drug reactions in patients managing multiple medications. This resource equips prescribers with structured tools for identifying, assessing, and mitigating high-risk CYP450 interactions before patient harm occurs. From real-world clinical scenarios to evidence-based deprescribing frameworks, this guide bridges pharmacokinetic theory and frontline practice. EdMedRxP Clinical Pharmacology Mon, 27 Jul 2026 16:26:40 GMT https://edmedrxp.com/glp-1-receptor-agonists-off-label-use-insurance-coverage-ethics-2024/ https://edmedrxp.com/glp-1-receptor-agonists-off-label-use-insurance-coverage-ethics-2024/ GLP-1 receptor agonists have moved far beyond their origins as glucose-lowering agents, generating intense clinical interest and patient demand across weight management, cardiovascular medicine, and emerging therapeutic areas. Yet the prescribing landscape in 2024 is defined as much by insurance inconsistencies and ethical complexity as it is by promising clinical evidence. This article provides healthcare providers with practical guidance on navigating FDA approvals, off-label prescribing oblig EdMedRxP Prescribing Practice & Policy Mon, 27 Jul 2026 16:26:40 GMT